PMV Pharmaceuticals
Market cap $92.2M 75.5M shares (10-Q, Nov 10, 2026) × $1.22 close Nov 17, 2026
Most recent annual filing: 2026-03-06
- Rezatapopt toplineNov 20, 2026Rezatapopt topline, Nov 20, 2026, thesis-defining
- Rezatapopt NDA filing1Q 2027Rezatapopt NDA filing, 1Q 2027, material
- company corporate update1Q 2028company corporate update, 1Q 2028, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (7 active programs)
Technology platforms
Precision Oncology Platform
Small molecule discovery and development platform targeting p53 mutations and p53-related cancers; leverages structural biology, assays, and biomarkers to identify and optimize selective small molecules that structurally correct specific mutant p53 proteins to restore wild-type function; disease focus is tumor-agnostic oncology defined by p53 genomic alterations.
Targets: p53
Capital (as filed)
- Cash
- $20.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $82.6M Sep 30, 2026
- Long-term investments
- $6.0M Sep 30, 2026
- Operating cash flow
- −$18.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $109M cash, runway Q1 2028 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure
Offering documents (2)
- 2026-09-02 424B5 · Priced offering 22.1M shares · at $1.21 · $50.8M gross · 6.2% below the prior close ($1.29, Sep 1, 2026) · incl. pre-funded warrants
- 2026-08-31 424B3 · At-the-market program up to $114M
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (7)
- 2026-11-11 UPDATE: PMV Pharma (PMVP) - The Going Concern Flag Comes Down
- 2026-09-02 UPDATE: PMV Pharma (PMVP) - The Blanks Get Filled In 🔒 Paid
- 2026-08-31 UPDATE: PMV Pharma (PMVP) - The Raise Finally Comes, Wrapped in Warrants 🔒 Paid
- 2026-08-15 UPDATE: PMV Pharma (PMVP) - The Going Concern Flag Goes Up 🔒 Paid
- 2026-05-12 UPDATE: PMV Pharma (PMVP) - The ORR Shrinks, The NEJM Validates, The Clock Tightens
- 2026-03-08 UPDATE: PMV Pharma (PMVP) - The Data Gets Stronger... 🔒 Paid
- 2026-02-16 PMV Pharmaceuticals (PMVP): Scientific Deep Dive for Rezatapopt 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (7 calls)
Every verdict Biotech Distilled has published on PMV Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-02-16 Watch PMV Pharmaceuticals (PMVP): Scientific Deep Dive for Rezatapopt Elegant p53 Y220C reactivation science with compelling ovarian cancer ORR, but a critical dilution gap and imminent cash crunch make the equity precarious until the balance sheet is fortified.
- 2026-03-08 Watch UPDATE: PMV Pharma (PMVP) - The Data Gets Stronger... ORR improved to 50% and Orphan Drug Designation secured, but OrbiMed's full liquidation and the unchanged dilution gap support staying on the sidelines until the balance sheet is cleared.
- 2026-05-12 Watch UPDATE: PMV Pharma (PMVP) - The ORR Shrinks, The NEJM Validates, The Clock Tightens ORR drifted from 50% to 44% confirmed as denominator grew, NEJM validated the mechanism, but a dilutive raise is now a mathematical certainty and management's ATM inaction signals a timing gamble rather than a plan.
- 2026-08-15 Watch UPDATE: PMV Pharma (PMVP) - The Going Concern Flag Goes Up Auditors issued a formal going-concern warning while PYNNACLE enrollment completed, making the financing overhang officially disclosed and forcing a near-term resolution, but buying before the raise means paying for a capital structure that does not yet exist.
- 2026-08-31 Speculative buy speculative UPDATE: PMV Pharma (PMVP) - The Raise Finally Comes, Wrapped in Warrants The long-awaited financing event is underway, duration of response improved to 10.0 months, and the ORR stabilized with a locked denominator, but the upgrade is conditional on final offering terms not yet printed.
- 2026-09-02 Speculative buy speculative UPDATE: PMV Pharma (PMVP) - The Blanks Get Filled In Offering priced at market ($1.21, no discount), oversubscribed, raising ~$110M pro forma to fund through the Q1 2027 NDA and review cycle, retiring the objection that the capital structure did not yet exist.
- 2026-11-11 Speculative buy speculative UPDATE: PMV Pharma (PMVP) - The Going Concern Flag Comes Down Going-concern language formally withdrawn, runway extended to Q1 2028, commercial chief hired, and specialist fund takes board seat — the financing problem is solved ahead of the ENA primary-analysis readout and Q1 2027 NDA submission.
- Long call · opened Sep 1, 2026 at $1.29 · -5.4% vs XBI -11.1% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We plan to submit our initial New Drug Application, or NDA, via accelerated approval for platinum resistant/refractory ovarian cancer in the first quarter of 2027.”
matched to Rezatapopt · regulatory submission
-
-
-
“We plan to submit our initial New Drug Application, or NDA, via accelerated approval for platinum resistant/refractory ovarian cancer in the first quarter of 2027.”
matched to Rezatapopt · regulatory submission
-
-
-
“We plan to submit a New Drug Application, or NDA, for the treatment of patients with platinum-resistant/refractory ovarian cancer harboring a TP53 Y220C mutation to the FDA for rezatapopt in the first quarter of 2027.”
matched to Rezatapopt · regulatory submission
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (27)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 10, 2026ReleasePMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights→ BD updateSummary on the 8-K
- Nov 10, 20268-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q formally lifts the going-concern flag, extends cash runway to Q1 2028, and PMV hired its first Chief Commercial Officer — signaling the team now believes approval is a matter of when, not if, with the pivotal PYNNACLE readout at ENA 2026 still ahead.
- Nov 10, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 4, 2026ReleasePivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026
- Oct 5, 2026ReleasePMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
- Oct 5, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1BD extracted 1 program update from this document → PMVP pipeline
- Sep 8, 2026ReleasePMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
- Sep 2, 20268-KCurrent report: material agreement, other events · EX-99.1
- Sep 2, 2026424B5Prospectus supplement (offering)
- Aug 31, 2026ReleasePMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial→ BD updateSummary on the 8-K
- Aug 31, 2026ReleasePMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities→ BD updateSummary on the 8-K
- Aug 31, 2026ReleasePMV Pharma Announces Proposed Public Offering of Securities→ BD updateSummary on the 8-K
- Aug 31, 20268-KCurrent report: other events · EX-99.1→ BD updateToday PMVP dropped two punches simultaneously: the PYNNACLE May data cut shows ORR holding at 46% (35/76) while median duration of response vaulted to 10.0 months — and in the same breath, management finally pulled the trigger on the dilution event I've been warning about since the original deep dive, killing the ATM and launching an underwritten secondary with warrants via TD Cowen.BD extracted 1 program update from this document → PMVP pipeline
- Aug 31, 2026424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- Aug 31, 2026424B3Prospectus (resale / update)→ BD updateSummary on the 8-K
- Aug 14, 2026ReleasePMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate HighlightsBD extracted 1 program update from this document → PMVP pipeline
- Aug 14, 20268-KCurrent report: results of operations · EX-99.1
- Aug 14, 202610-QQuarterly report
- Jun 5, 20268-KCurrent report: shareholder vote
- May 12, 2026ReleasePMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- Apr 22, 2026DEFA14AProxy soliciting material
- Apr 22, 2026DEF 14AProxy statement
- Mar 6, 20268-KCurrent report: results of operations · EX-99.1
- Mar 6, 202610-KAnnual report
- Mar 4, 2026SCHEDULE 13D/A13D amendment
8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Sep 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 28, 2026SCHEDULE 13G/A13G amendment
- Jul 10, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 4, 2026SCHEDULE 13G/A13G amendment
- Apr 22, 2026ARSAnnual report to shareholders
- Mar 6, 2026S-8Employee plan registration